Purdue Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for PURDUE PHARMA, and when can generic versions of PURDUE PHARMA drugs launch?
PURDUE PHARMA has eleven approved drugs.
There are forty-six US patents protecting PURDUE PHARMA drugs.
There are four hundred and fifty-seven patent family members on PURDUE PHARMA drugs in fifty-one countries and eight supplementary protection certificates in five countries.
Summary for Purdue Pharma
International Patents: | 457 |
US Patents: | 46 |
Tradenames: | 11 |
Ingredients: | 11 |
NDAs: | 11 |
Patent Litigation for Purdue Pharma: | See patent lawsuits for Purdue Pharma |
PTAB Cases with Purdue Pharma as petitioner: | See PTAB cases with Purdue Pharma as petitioner |
PTAB Cases with Purdue Pharma as patent owner: | See PTAB cases with Purdue Pharma as patent owner |
Drugs and US Patents for Purdue Pharma
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Purdue Pharma Lp | HYSINGLA ER | hydrocodone bitartrate | TABLET, EXTENDED RELEASE;ORAL | 206627-007 | Nov 20, 2014 | AB | RX | Yes | No | 9,095,614 | ⤷ Try a Trial | ⤷ Try a Trial | |||
Purdue Pharma Lp | OXYCONTIN | oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022272-001 | Apr 5, 2010 | RX | Yes | No | 11,304,908 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Purdue Pharma Lp | OXYCONTIN | oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022272-005 | Apr 5, 2010 | RX | Yes | Yes | 9,492,393 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Purdue Pharma Lp | OXYCONTIN | oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022272-003 | Apr 5, 2010 | RX | Yes | No | 9,522,919 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Purdue Pharma
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Purdue Pharma Lp | HYSINGLA ER | hydrocodone bitartrate | TABLET, EXTENDED RELEASE;ORAL | 206627-001 | Nov 20, 2014 | 9,669,024 | ⤷ Try a Trial |
Purdue Pharma Lp | OXYCONTIN | oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 022272-004 | Apr 5, 2010 | 9,060,976 | ⤷ Try a Trial |
Purdue Pharma Lp | BUTRANS | buprenorphine | FILM, EXTENDED RELEASE;TRANSDERMAL | 021306-004 | Jul 25, 2013 | 6,264,980 | ⤷ Try a Trial |
Purdue Pharma Lp | TARGINIQ | naloxone hydrochloride; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205777-003 | Jul 23, 2014 | 6,277,384 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for PURDUE PHARMA drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Sublingual Tablets | 1.75 mg and 3.5 mg | ➤ Subscribe | 2012-04-10 |
➤ Subscribe | Transdermal System | 15 mcg/hr | ➤ Subscribe | 2013-12-16 |
➤ Subscribe | Extended-release Tablets | 30 mg, 40 mg, 80 mg, and 100 mg | ➤ Subscribe | 2015-05-08 |
➤ Subscribe | Extended-release Tablets | 30 mg and 60 mg | ➤ Subscribe | 2007-01-03 |
➤ Subscribe | Extended-release Tablets | 100 mg, 200 mg and 300 mg | ➤ Subscribe | 2009-06-18 |
➤ Subscribe | Transdermal System | 5 mcg/hr, 10 mcg/hr, and 20 mcg/hr | ➤ Subscribe | 2013-06-06 |
➤ Subscribe | Extended-release Tablets | 20 mg, 60 mg, and 120 mg | ➤ Subscribe | 2015-04-15 |
➤ Subscribe | Extended-release Tablets | 15 mg | ➤ Subscribe | 2007-02-15 |
International Patents for Purdue Pharma Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | 2011157370 | ⤷ Try a Trial |
Hong Kong | 1165317 | ⤷ Try a Trial |
Israel | 241122 | ⤷ Try a Trial |
Montenegro | 01299 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Purdue Pharma Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2236132 | 122015000006 | Germany | ⤷ Try a Trial | PRODUCT NAME: ZOLPIDEM UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; NAT. REGISTRATION NO/DATE: 83439.00.00 83440.00.00 20120725 FIRST REGISTRATION: BELGIEN BE424286 BE424295 20120718 |
2236132 | C300714 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NAT. REGISTRATION NO/DATE: RVG 108438 - 439 20130624; FIRST REGISTRATION: BE424286BE424295 2012180718 |
2236132 | 92636 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: ZOLPIDEM ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES |
1685839 | 92292 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: COMBINAISON D OXYCODONE EN TANT QUE COMPOSANT A ET DE NALOXONE EN TANT QUE COMPOSANT B SOUS TOUTES LES FORMES PROTEGES PAR LE BREVET DE BASE |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.